NRx Pharmaceuticals, Inc.(NRXP)Earnings, Financials & Key RatiosNRx Pharmaceuticals, Inc. (NRXP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
Negative: The company's current ratio of 0.29 and consistent quarterly free cash flow burn of $4.3 million suggest a high probability of future shareholder dilution to maintain operations.
NRx Pharmaceuticals, Inc. (NRXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
NRx Pharmaceuticals, Inc. (NRXP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.04vs $0.05+20.0% | $1Mvs $19M-94.5% |
| Q2 2026 | Mar 23, 2026 | $0.19vs $0.09+311.1% | $983,000vs $8M-86.9% |
| Q4 2025 | Nov 14, 2025 | $0.18vs $0.11-63.6% | $242,000vs $8M-96.8% |
| Q2 2025 | May 15, 2025 | $0.34vs $0.30-13.3% | $2M |
Recent stock market news and headlines for NRx Pharmaceuticals, Inc. (NRXP)
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute (“Kadima”).
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered, sub-millimetric image guidance is now being applied in HOPE's outpatient TMS workflows for patients with Major Depressive Disorder and other CNS conditions Milestone advances HOPE's interventional psychiatry platform and aligns with NRx's planned trial of NRX-101 in combination with robotic-enabled TMS in civilian and military treatment facilities (the SPARC-TMS trial). WILMINGTON, Del.
SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and two of its subsidiaries in San Diego County Superior Court, alleging breach of contract and misrepresentation in connection with an acquisition agreement that the defendants warranted they had the financial capacity to close. The planned transaction represents a significant percentage of NRx's current market capitalization. T.
SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota. HOPE has installed Zeta TMS Navigation Systems at clinics in West Palm Beach and Sarasota, with Zeta-navigated patient treatments beginning at both locations this week.
WILMINGTON, Del., June 22, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the approval by FDA of an Intermediate Population Expanded Access Protocol for the use of NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone for the augmentation of accelerated Transcranial Magnetic Stimulation (TMS). Expanded Access Protocols are part of FDA's compassionate care approach to making investigational drugs available to patients with serious or life-threatening medical conditions1.
Key metrics vs top competitors for NRx Pharmaceuticals, Inc. (NRXP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.95 | $68.19M | -2.94 | — | -2336.49% | — | — | |
| $242.60 | $12.48B | -65.92 | 65.55% | -26.59% | -260.01% | — | |
| $5.72 | $442.11M | 35.75 | -4.9% | 3.16% | 12.53% | — | |
| $1.67 | $44.26M | -0.90 | 257.14% | — | -170.86% | — | |
| $4.96 | $1.83B | -1.70 | 1227.6% | -19019.44% | -366.21% | — | |
| $12.84 | $1.23B | -4.17 | — | — | -151.02% | — |
NRx Pharmaceuticals, Inc. (NRXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRx Pharmaceuticals, Inc. (NRXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 24, 2026·SEC
Feb 17, 2026·SEC
Feb 17, 2026·SEC
Get notified when NRXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRx Pharmaceuticals, Inc. (NRXP) stock FAQ — growth, dividends, profitability & financials explained
NRx Pharmaceuticals, Inc. (NRXP) reported $2.3M in revenue for fiscal year 2025.
NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $24.5M for fiscal year 2025.
NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $14.9M in fiscal year 2025, likely due to heavy capital investments.
